New Therapeutic Options Could Shift Prostate Cancer Treatment (APAC)

Max Nisen

Analyst

Bloomberg Intelligence

Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.

Sam Fazeli

Head of EMEA Research

Bloomberg

Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI . Dr. Fazeli specializes in global pharmaceuticals, bringing over 20 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Dr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Dr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.